Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384436 · ClinicalTrials.gov registry record · Phase 4
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
A Phase 4 study of Major Depressive Disorder, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 580
- Enrollment target
- 1
- Study location
NCT00384436 is a Phase 4 study of Major Depressive Disorder that has completed, run by Forest Laboratories. The registered enrollment target is 580 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00384436, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 580 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of escitalopram to an active comparator in severely depressed patients
Conditions Studied
Interventions
- DRUG escitalopram
Study Locations (1)
Missouri
- For information regarding investigative sites, contact Forest Professional Affairs - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384436
The ClinicalTrials.gov registry entry for NCT00384436 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% higher). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which escitalopram is the first listed.
NCT00384436 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00384436 about?
NCT00384436 is a clinical study titled "Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients". The purpose of this study is to evaluate the safety and efficacy of escitalopram to an active comparator in severely depressed patients
What is the current status of trial NCT00384436?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 580 participants. The study started on 2006-10.
What conditions does trial NCT00384436 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00384436?
The interventions under investigation include: escitalopram (DRUG).
Who is sponsoring clinical trial NCT00384436?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00384436 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.